Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research eventBALTIMORE and PALO ALTO, Calif., April 25, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc ., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced its team is presenting at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. DELFI is showcasing its groundbreaking DELFI-TF technology for treatment response monitoring alongside its early detection capabilities."Our presentations at AACR highlight how DELFI's fragmentomics platform is transforming both early cancer detection and treatment monitoring," said Victor E. Velculescu, MD, PhD, DELFI Diagnostics Founder and Board Director. "The DELFI technology represents a paradigm shift in how we detect cancer by combining genome-wide fragmentomics of DNA in the blood with AI algorithms for high sensitivity in the screening setting as well as for noninvasively measuring treatment efficacy in advanced cancer patients. "DELFI is presenting multiple podium and poster sessions at AACR, including:Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection presented by Victor E. Velculescu, MD, PhDTuesday, April 29 , 11:06 AM - 11:26 AM CT, Room S100 BC (Grand Ballroom BC) - McCormick Place SouthLeveraging the cfDNA fragmentome to predict immunotherapy response presented by Valsamo Anagnostou, MD, PhDMonday, April 28 , 3:05 PM - 3:20 PM CT, Room S105 - McCormick Place SouthAnalysis of lung cancer clinical characteristics using cell-free DNA fragmentomes presented by Lorenzo Rinaldi, PhDMonday, April 28 , 9:00 AM - 12:00 PM CT, Section 28, Poster 29Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the DOLPHIN study presented by Denise E

Canton-based Delfi Diagnostics has named Robert Guigley as its new chief commercial officer.